Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab in bullous pemphigoid
2019-001529-28Phase 2Completed
- Sponsor
- CHU de Reims
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ustekinumab in Bullous Pemphigoid (BP), sponsored by CHU de Reims. Primary endpoint: Complete remission at 28 weeks without specific bullous pemphigoid treatment since the end of week 8. Started May 2019; status: completed.
02
Drugs
ustekinumab
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on 2019-001529-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001529-28.